Last reviewed · How we verify
Ceftriaxone intravenous
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking cross-linking of peptidoglycan.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking cross-linking of peptidoglycan. Used for Bacterial infections (meningitis, pneumonia, gonorrhea, Lyme disease, sepsis), Surgical prophylaxis.
At a glance
| Generic name | Ceftriaxone intravenous |
|---|---|
| Also known as | generic name: ceftriaxone, Pharmaceutical form: solution for infusion, ATC code:J01DA |
| Sponsor | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
| Drug class | Third-generation cephalosporin |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Ceftriaxone is a third-generation cephalosporin antibiotic that penetrates bacterial cell walls and irreversibly binds to penicillin-binding proteins, preventing the cross-linking of peptidoglycan strands. This disrupts cell wall integrity, leading to bacterial cell lysis and death. It has broad-spectrum activity against gram-positive and gram-negative bacteria, with particularly strong activity against aerobic gram-negative organisms.
Approved indications
- Bacterial infections (meningitis, pneumonia, gonorrhea, Lyme disease, sepsis)
- Surgical prophylaxis
Common side effects
- Diarrhea
- Rash
- Phlebitis at injection site
- Nausea
- Hypersensitivity reactions
Key clinical trials
- Study of Ceftriaxone and Benzathine Penicillin G During Pregnancy
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial (NA)
- Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP (PHASE4)
- PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury (PHASE3)
- Prophylactic Antibiotics in Endoscopic Secondary Prevention of Gastroesophageal Variceal Bleeding (NA)
- 3-day IV Antibiotic Treatment Versus 3-day IV Followed by 7-day Oral Antibiotic Treatment for AP in Children (PHASE4)
- Enhanced Molecular Microbiological Surveillance Versus Ceftriaxone Prophylaxis in Hematopoietic Cell Transplant Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: